Shots:

• The company reported the results from the P-I study to evaluates omalizumab biosimilar CT-P39 vs Genentech’ Xolair in 176 healthy patients aged b/w 18 & 55yrs. with asthma & CIU. The therapy was given as 150mg dose of CT-P39, EU & US-Xolair
• The results showed similar safety & PK profiles to Xolair, 62 patients received biosimilar, 64 received the EU-Xolair & 50 US-Xolair, mean serum concentrations were similar b/w the treatment groups
• The company has launched omalizumab biosimilar Genolar in Russia in Feb 2022 for persistent atopic bronchial asthma & resistant CIU aged ≥6yrs. under the agreement b/w selexis & generium. Omalizumab is an anti-inflammatory agent that binds to free IgE resulting in a reduction of free IgE & increase in total IgE

Ref: Center For Biosimilars | Image: Celltrion